PREPIDIL® Contraindications

(dinoprostone)

CONTRAINDICATIONS

Endocervically administered PREPIDIL Gel is not recommended for the following:

a.

Patients in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, such as:

cases with a history of cesarean section or major uterine surgery
cases in which cephalopelvic disproportion is present
cases in which there is a history of difficult labor and/or traumatic delivery
grand multiparae with six or more previous term pregnancies cases with non-vertex presentation
cases with hyperactive or hypertonic uterine patterns
cases of fetal distress where delivery is not imminent
in obstetric emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention

b.

Patients with hypersensitivity to prostaglandins or constituents of the gel (see WARNINGS and ADVERSE REACTIONS).

c.

Patients with placenta previa or unexplained vaginal bleeding during this pregnancy.

d.

Patients for whom vaginal delivery is not indicated, such as vasa previa or active herpes genitalia.

Find PREPIDIL® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREPIDIL® Quick Finder

Prescribing Information

Download Prescribing Information

Health Professional Information

Contraindications

CONTRAINDICATIONS

Endocervically administered PREPIDIL Gel is not recommended for the following:

a.

Patients in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, such as:

cases with a history of cesarean section or major uterine surgery
cases in which cephalopelvic disproportion is present
cases in which there is a history of difficult labor and/or traumatic delivery
grand multiparae with six or more previous term pregnancies cases with non-vertex presentation
cases with hyperactive or hypertonic uterine patterns
cases of fetal distress where delivery is not imminent
in obstetric emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention

b.

Patients with hypersensitivity to prostaglandins or constituents of the gel (see WARNINGS and ADVERSE REACTIONS).

c.

Patients with placenta previa or unexplained vaginal bleeding during this pregnancy.

d.

Patients for whom vaginal delivery is not indicated, such as vasa previa or active herpes genitalia.

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985^*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.